Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2024 on Tuesday, May 14, 2024, at the Encore Hotel, Las Vegas, Nevada.
佛羅里達州科勒爾蓋布爾斯，2024年5月1日（GLOBE NEWSWIRE）——Catalyst Pharmicals, Inc.（“Catalyst” 或 “公司”）（納斯達克股票代碼：CPRX）是一家商業階段的生物製藥公司，專注於爲罕見和難以治療的疾病患者進行新藥的授權、開發和商業化今天宣佈，Catalyst總裁兼首席執行官理查德·戴利以及Catalyst的其他成員的管理團隊將參加即將於2024年5月14日星期二在拉斯維加斯安可酒店舉行的2024年美銀證券醫療保健會議，內華達。
Presentation Details:
演示詳情：
| Date: | Tuesday, May 14, 2024 | |
| Time: | 5:00 pm PT |
| 日期： | 2024 年 5 月 14 日，星期二 | |
| 時間： | 太平洋時間下午 5:00 |
The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 14 days.
網絡直播將在公司網站的 “投資者” 部分下播出， www.coatalystpharma.com，並且重播將持續至少 14 天。
About Catalyst Pharmaceuticals, Inc.
Catalyst 製藥公司簡介
With exceptional patient focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare and difficult-to-treat diseases. Catalyst's flagship U.S. commercial product is FIRDAPSE (amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for adults and for children ages six to seventeen. In January 2023, Catalyst acquired the U.S. commercial rights to FYCOMPA (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. On July 18, 2023, Catalyst acquired an exclusive license for North America for AGAMREE (vamorolone) oral suspension 40 mg/mL, a novel corticosteroid treatment for Duchenne Muscular Dystrophy. AGAMREE previously received FDA Orphan Drug and Fast Track designations and was approved by the FDA for commercialization in the U.S. on October 26, 2023. AGAMREE became commercially available by prescription in the U.S. on March 13, 2024.
Catalyst以患者爲中心，致力於開發和商業化治療罕見和難以治療的疾病的同類首創藥物。Catalyst 在美國的旗艦商用產品是 FIRDAPSE （amifampridine）片劑10 mg，獲准用於治療成人和六至十七歲兒童的蘭伯特-伊頓肌無力綜合徵（“LEMS”）。2023 年 1 月，Catalyst 收購了 FYCOMPA 的美國商業版權 （perampanel）CIII，一種處方藥獲准單獨用於四歲及以上的癲癇患者，或與其他藥物合用，用於治療伴有或沒有繼發性全身性發作的部分發作性癲癇發作，以及其他治療12歲及以上癲癇患者原發性全身性強直陣攣發作的藥物。此外，加拿大國家醫療監管機構加拿大衛生部已批准使用FIRDAPSE在加拿大使用LEMS治療成年患者。2023 年 7 月 18 日，Catalyst 獲得了 AGAMREE 的北美獨家許可 （vamorolone）口服混懸液40 mg/mL，一種治療杜興氏肌肉萎縮症的新型皮質類固醇藥物。AGAMREE此前曾獲得美國食品藥品管理局孤兒藥和快速通道認定，並於2023年10月26日獲得美國食品藥品管理局批准在美國商業化。AGAMREE 於 2024 年 3 月 13 日在美國通過處方上市。
For more information about Catalyst Pharmaceuticals, Inc., please visit the Company's website at www.catalystpharma.com. For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com. For Full Prescribing Information, including Boxed WARNING for FYCOMPA, please visit www.fycompa.com. For Full Prescribing Information for AGAMREE, please visit www.agamree.com.
有關 Catalyst Pharmicals, Inc. 的更多信息，請訪問該公司的網站 www.coatalystpharma.com。有關 FIRDAPSE 的完整處方和安全信息，請訪問 www.firdapse.com。獲取完整處方信息，包括 FYCOMPA 的盒裝警告，請訪問 www.fycompa.com。有關 AGAMREE 的完整處方信息，請訪問 www.agamree.com。
Forward-Looking Statements
前瞻性陳述
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
本新聞稿包含前瞻性陳述，該術語的定義見1995年《私人證券訴訟改革法》。前瞻性陳述涉及已知和未知的風險和不確定性，這可能導致Catalyst在未來時期的實際業績與預測的業績存在重大差異。許多因素，包括Catalyst的2023財年10-K表年度報告及其向美國證券交易委員會（“SEC”）提交的其他文件中描述的因素，可能會對Catalyst產生不利影響。Catalyst向美國證券交易委員會提交的文件副本可從美國證券交易委員會獲得，也可以在Catalyst的網站上找到，也可以應Catalyst的要求獲得。Catalyst不承擔任何義務更新此處包含的信息，這些信息僅限於截至該日期。
Source: Catalyst Pharmaceuticals, Inc.
資料來源：Catalyst 製藥公司
Investor Contact Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 mcoleman@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com
投資者聯繫人瑪麗·科爾曼，Catalyst Pharmicals, Inc. (305) 420-3200 mcoleman@catalystpharma.com 媒體聯繫人 David Schull，Russo Partners (858) 717-2310 david.schull@russopartnersllc.com
Source: Catalyst Pharmaceuticals, Inc.
資料來源：Catalyst 製藥公司
譯文內容由第三人軟體翻譯。